Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus

Background: Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having optimal cardioprotective properties. A comparative study of the various sodium-glucose co-tr...

Full description

Bibliographic Details
Main Authors:	A. V. Simanenkova, S. M. Minasian, T. L. Karonova, T. D. Vlasov, N. V. Timkina, А. K. Khalzova, O. S. Fuks, A. A. Shimshilashvili, V. A. Timofeeva, Yu. Yu. Borshchev, M. M. Galagudza
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2021-07-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus myocardial infarction cardioprotection empagliflozin canagliflozin sitagliptin
Online Access:	https://www.dia-endojournals.ru/jour/article/view/12714

Similar Items

Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
by: Haitham G. Zakaraia, et al.
Published: (2023-11-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS
by: Marina V. Shestakova
Published: (2019-12-01)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
by: Ghetti G, et al.
Published: (2023-02-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Comparative study on efficacy of empagliflozin versus sitagliptin, as an add-on therapy to metformin in type 2 diabetic patients
by: Harsh Salankar, et al.
Published: (2024-01-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
by: Xiaoyu Pan, et al.
Published: (2022-10-01)

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023-07-01)

Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
by: Matthew Griffin, et al.
Published: (2020-08-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)

Cardioprotective Effect of Quercetin and Sitagliptin in Doxorubicin-Induced Cardiac Toxicity in Rats
by: Aziz TA
Published: (2021-03-01)

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
by: Julia Hoehlschen, et al.
Published: (2023-04-01)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
by: Manuel Alfredo Podestà, et al.
Published: (2023-01-01)

Acute canagliflozin treatment protects against in vivo myocardial ischemia–reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
by: Alex Ali Sayour, et al.
Published: (2019-04-01)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
by: Klaudia Kowalska, et al.
Published: (2021-12-01)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
by: Agnes Bosch, et al.
Published: (2023-06-01)

Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
by: Sanjay Kalra, et al.
Published: (2018-01-01)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019-04-01)

Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
by: Ha Young Jang, et al.
Published: (2022-08-01)

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects
by: Ioanna Andreadou, et al.
Published: (2017-12-01)

Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
by: Nina A. Petunina, et al.
Published: (2016-12-01)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes
by: Silvia Giannattasio, et al.
Published: (2022-05-01)

Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
by: Elmar Zügner, et al.
Published: (2022-07-01)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Synthesis of New Derivatives of Berberine Canagliflozin and Study of Their Antibacterial Activity and Mechanism
by: Jinsheng Li, et al.
Published: (2024-01-01)

Synthesis of Berberine and Canagliflozin Chimera and Investigation into New Antibacterial Activity and Mechanisms
by: Wenhui Hao, et al.
Published: (2022-05-01)

Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia
by: Ruhua Deng, et al.
Published: (2022-10-01)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
by: Masahiro Fukuda, et al.
Published: (2019-03-01)

Oxidative stress markers in liver in streptozocin-induced diabetic rats: effects of metformin and sitagliptin
by: Şamil Öztürk, et al.
Published: (2020-12-01)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
by: Aaron Y. Kluger, et al.
Published: (2019-08-01)

Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression
by: Kannan Sridharan, et al.
Published: (2024-03-01)

SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
by: Mieczysław Dutka, et al.
Published: (2022-11-01)

Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
by: Pei-Chien Tsai, et al.
Published: (2023-03-01)

Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients
by: Cesar Ernesto Lam-Chung
Published: (2023-07-01)

Effect of SGLT2 inhibitors on the course of chronic heart failure in patients with type 2 diabetes mellitus
by: A. N. Payudis, et al.
Published: (2022-10-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles
by: Afzal Haq Asif, et al.
Published: (2018-05-01)